Advanz Pharma (OTCMKTS:CXRXF) Hits New 1-Year Low at $9.79

Advanz Pharma Corp (OTCMKTS:CXRXF) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $9.79 and last traded at $9.79, with a volume of 140 shares traded. The stock had previously closed at $10.89.

CXRXF has been the topic of several analyst reports. ValuEngine upgraded Advanz Pharma from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research lowered Advanz Pharma from a “hold” rating to a “sell” rating in a report on Wednesday.

The stock has a market cap of $475.89 million, a price-to-earnings ratio of 0.83 and a beta of 0.50. The business has a 50-day simple moving average of $13.57 and a two-hundred day simple moving average of $15.86. The company has a debt-to-equity ratio of 6.47, a current ratio of 2.01 and a quick ratio of 1.71.

Advanz Pharma (OTCMKTS:CXRXF) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.03. Advanz Pharma had a negative return on equity of 55.04% and a net margin of 322.43%. The company had revenue of $131.08 million during the quarter, compared to analysts’ expectations of $127.00 million. As a group, equities analysts anticipate that Advanz Pharma Corp will post -2.09 earnings per share for the current fiscal year.

Advanz Pharma Company Profile (OTCMKTS:CXRXF)

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Recommended Story: What is a Market Correction?

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.